Akero’s cash, cash equivalents and short and long-term marketable securities as of June 30, 2024, were $848.3 million. Akero believes that its current cash, cash equivalents, and short- and long-term marketable securities will be sufficient to fund its Phase 3 SYNCHRONY Histology and Real-World studies through readout of their respective primary endpoints and Akero’s current operating plan into the second half of 2027.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AKRO:
- Akero Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
- Class Action Lawsuit against Akero Therapeutics, Inc. (NASDAQ:AKRO)
- Akero Therapeutics Announces Initiation of Phase 3 SYNCHRONY Outcomes Trial of Efruxifermin in Patients with Compensated Cirrhosis (F4) Due to MASH
- Akero Therapeutics announces initiation of Phase 3 SYNCHRONY outcomes trial
- Akero Therapeutics initiated with an Outperform at Wolfe Research